Compare CYPH & BTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYPH | BTMD |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | 6 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.4M | 71.0M |
| IPO Year | N/A | 2021 |
| Metric | CYPH | BTMD |
|---|---|---|
| Price | $0.76 | $2.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.83 |
| AVG Volume (30 Days) | ★ 6.8M | 191.0K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 722.22 |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | ★ $192,219,000.00 |
| Revenue This Year | N/A | $2.03 |
| Revenue Next Year | N/A | $6.58 |
| P/E Ratio | ★ N/A | $37.67 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.49 | $1.27 |
| 52 Week High | $3.70 | $4.75 |
| Indicator | CYPH | BTMD |
|---|---|---|
| Relative Strength Index (RSI) | 43.75 | 53.96 |
| Support Level | $0.54 | $1.97 |
| Resistance Level | $0.79 | $2.37 |
| Average True Range (ATR) | 0.11 | 0.16 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 31.82 | 58.41 |
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.